Clinical data | |
---|---|
Trade names | Byfavo |
Other names | Remimazolam besylate, CNS-7056[1] |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous |
Drug class | Benzodiazepine[2] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Duration of action | 10 min[4] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H19BrN4O2 |
Molar mass | 439.313 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Remimazolam, sold under the brand name Byfavo, is a medication used for procedural sedation.[3] Specifically it is used in adults for procedures lasting less than 30 minutes.[3] It is given by injection into a vein.[3] While onset of effects is similar, the duration is shorter than midazolam.[5][6]
Common side effects include low blood pressure, high blood pressure, and low oxygen.[3] Other side effects may include abuse and allergic reactions.[3] Effectiveness is not altered in kidney problems, though lower doses may be used in those with liver problems.[3][7] Effects can be revered with flumazenil.[4] It is a benzodiazepine and works by attaching to gamma-amino butyric acid (GABA) receptors.[2]
Remimazolam was approved for medical use in the United States in 2020 and Europe in 2021.[3][2] In the United States a vial of 20 mg costs about 42 USD as of 2022.[8]
References
edit- ^ Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. (2007). "CNS 7056: a novel ultra-short-acting Benzodiazepine". Anesthesiology. 107 (1): 60–6. doi:10.1097/01.anes.0000267503.85085.c0. PMID 17585216. S2CID 19504961.
- ^ a b c d "Byfavo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 21 April 2021. Retrieved 20 April 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g h i j "Byfavo- remimazolam besylate injection, powder, lyophilized, for solution". DailyMed. 20 July 2020. Archived from the original on 22 October 2022. Retrieved 25 February 2021.
- ^ a b Kaye, Alan David (5 June 2017). Pharmacology, An Issue of Anesthesiology Clinics. Elsevier Health Sciences. p. e101. ISBN 978-0-323-52998-3. Archived from the original on 12 November 2022. Retrieved 3 November 2022.
- ^ Noor, N; Legendre, R; Cloutet, A; Chitneni, A; Varrassi, G; Kaye, AD (2021). "A comprehensive review of remimazolam for sedation". Health psychology research. 9 (1): 24514. doi:10.52965/001c.24514. PMID 34746482.
- ^ Goudra, BG; Singh, PM (July 2014). "Remimazolam: The future of its sedative potential". Saudi journal of anaesthesia. 8 (3): 388–91. doi:10.4103/1658-354X.136627. PMID 25191193.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ "Remimazolam Monograph for Professionals". Drugs.com. Retrieved 3 November 2022.
- ^ "Byfavo Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 29 May 2022. Retrieved 3 November 2022.